[Endothelins and chronic cardiac insufficiency]

Related Experiment Video

Updated: Oct 13, 2026

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research
08:42

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research

Published on: October 22, 2014

L Bartůnĕk

    Vnitrni Lekarstvi
    |August 23, 2000
    PubMed

    Insights

    Endothelins (ET), particularly ET-1, are potent vasoconstrictors implicated in cardiac insufficiency and pulmonary hypertension. Blocking ET pathways shows promise in managing heart failure by mitigating vasoconstriction and fluid retention.

    Area of Science:

    • Cardiovascular Physiology
    • Endocrinology

    Context:

    • Endothelins (ET) are regulatory substances with significant roles in various bodily systems.
    • Endothelin-1 (ET-1) is the primary cardiovascular ET and the most potent known vasoconstrictor.
    • ET-1 contributes to cardiac hypertrophy, vasoconstriction, impaired relaxation, and reduced contractility in heart failure.

    Purpose:

    • To elucidate the role of endothelins in cardiovascular pathophysiology, particularly in cardiac insufficiency.
    • To evaluate the diagnostic and prognostic utility of ET markers like Big-ET.
    • To assess the therapeutic potential of endothelin receptor blockers (ERBs) and endothelin-converting enzyme (ECE) inhibitors in heart failure.

    Summary:

    • ET-1 plays a critical role in the pathophysiology of cardiac insufficiency, promoting adverse cardiac remodeling and vasoconstriction, and is linked to pulmonary vascular hypertension.
    • Big-ET serves as a valuable neurohumoral marker for diagnosing advanced cardiac failure and improving prognostic stratification.
    • ET-1's significance in diagnosing cardiac insufficiency appears most pronounced in severe cases.
    • Therapeutic strategies involving ET blockade have demonstrated benefits. Non-selective ETA/ETB blockers and selective ETA blockers show favorable effects in cardiac insufficiency.
    • Selective ETB blockers may have adverse hemodynamic effects but can prevent fluid retention by suppressing aldosterone.
    • Inhibitors of endothelin-converting enzyme (ECE) are a promising therapeutic approach for heart failure, targeting overactivated neurohumoral factors.

    Impact:

    • Understanding the role of ET-1 in cardiac insufficiency informs diagnostic and prognostic strategies.
    • The efficacy of ET blockade in managing heart failure highlights potential therapeutic targets.
    • Selective ETB blockade's dual action on hemodynamics and fluid retention warrants further investigation.
    • ECE inhibitors represent a novel therapeutic avenue for heart failure, potentially offering a more targeted approach to neurohumoral imbalance.

    More Related Videos

    Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix10:21

    Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

    Published on: June 14, 2016

    Related Concept Videos

    Heart Failure II: Pathophysiology01:29

    Heart Failure II: Pathophysiology

    Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
    Imbalances in Cardiac Output01:26

    Imbalances in Cardiac Output

    The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
    CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
    Mitral Regurgitation I: Introduction01:20

    Mitral Regurgitation I: Introduction

    Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    Pathophysiology of Heart Failure01:17

    Pathophysiology of Heart Failure

    Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
    Heart Failure I: Introduction01:27

    Heart Failure I: Introduction

    Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...